The Contrast Media Market size in North America was valued at USD 1.65 Billion in 2020 and estimated to grow at a CAGR of 5.5%, worth USD 2.16 billion by 2025.
The rise in chronic diseases, such as cardiovascular and neurological diseases, is a significant factor in the growth of the US market. The development of minimally invasive treatments has encouraged the use of imaging equipment. The growing demand for image guidance is driving the North American contrast media market.
Increasing awareness of disease states and rising healthcare costs are factors that could drive North American Contrast Media Market during the forecast period. These include advanced imaging technologies such as ultrasound, x-ray, magnetic resonance imaging (MRI), and computed tomography (CT) scans. The role of these tests in determining the need for treatment/surgery in interventional procedures and preoperative scans is assumed to facilitate the use of contrast agents in imaging procedures and medical imaging, which has witnessed many advances recently. New technologies will improve medical images' resolution and quality and drive the demand for contrast agents and diagnostic radiopharmaceuticals in this locality.
The main challenges in North America Contrast Media Market are entry barriers due to safety issues with contrast agents.
This research report on the North American Contrast Media Market has been segmented and sub-segmented into the following categories:
By Medical Procedure:
By Route of Administration:
By Type:
By Indications:
By Application:
By Country:
Regional Analysis:
In terms of revenue, North America has the largest share of the global market. The USA has the highest demand, followed by Canada and Mexico. Developed countries such as the United States and Canada are increasingly aware of a prior diagnosis of disease. It is expected to drive market growth in the region. The infrastructure developed, increased investment in healthcare and strong R & D capabilities in countries in the area are other factors driving North America Contrast Media Market development.
The U.S. Contrast Media Market United States holds the highest market share in North America due to the use of diagnostic imaging modalities, such as MRI, CT, and ultrasound has increased rapidly in the United States. In the United States, there are around 40 million MRI scans performed annually. In addition to, increasing prevalence of cancer, the increase in chronic diseases, such as cardiovascular and neurological diseases, and accidental cases, which require medical imaging to investigate patient conditions at several stages of treatment, raise the demand for contrast medical market in this region.
The Canadian Contrast Media Market is expected to display significant growth in this region due to increasing R & D investments and a favorable demographic scenario in Canada. The rising prevalence of cancer in this region drives the market growth. In 2018, more than 200,000 Canadian people were diagnosed with cancer, and 80,000 died due to cancer. An increase in the acceptance of contrast agents and the rise in the number of diagnostic centers that have developed diagnostic imaging services are attributed to the market growth in Canada. The advanced techniques, such as in MRI imaging, the technology used is a gas microbubble anticipated the market's growth in the region.
Companies playing a dominant role in the North America Contrast Media Market profiled in this report are CMC Contrast AB (Sweden), Daiichi Sankyo (Japan), Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), Bracco Imaging S.p.A. (Italy), Lantheus Medical Imaging (U.S.), nanoPET Pharma GmbH (Germany), and Subhra Pharma Private Limited (India).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Medical Procedure
5.1.1 Introduction
5.1.2 X-Ray/CT
5.1.3 MRI
5.1.4 Ultrasound
5.1.5 Y-o-Y Growth Analysis, By Medical Procedure
5.1.6 Market Attractiveness Analysis, By Medical Procedure
5.1.7 Market Share Analysis, By Medical Procedure
5.2 Route of Administration
5.2.1 Introduction
5.2.2 Injectable Contrasts Media
5.2.3 Oral Contrasts Media
5.2.4 Rectal Contrasts Media
5.2.5 Urethral Contrasts Media
5.2.6 Y-o-Y Growth Analysis, By Route of Administration
5.2.7 Market Attractiveness Analysis, By Route of Administration
5.2.8 Market Share Analysis, By Route of Administration
5.3 Type
5.3.1 Introduction
5.3.2 Iodinated Contrasts Media
5.3.3 Gadolinium-Based Contrasts Media
5.3.4 Microbubble Contrasts Media
5.3.5 Barium- Based Contrasts Media
5.3.6 Y-o-Y Growth Analysis, By Type
5.3.7 Market Attractiveness Analysis, By Type
5.3.8 Market Share Analysis, By Type
5.4 Indications
5.4.1 Introduction
5.4.2 Cardiovascular Disorders
5.4.3 Oncology
5.4.4 Neurological Disorders
5.4.5 Gastrointestinal Disorders
5.4.6 Nephrological Disorders
5.4.7 Musculoskeletal Disorders
5.4.8 Y-o-Y Growth Analysis, By Indications
5.4.9 Market Attractiveness Analysis, By Indications
5.4.10 Market Share Analysis, By Indications
5.5 Application
5.5.1 Introduction
5.5.2 Radiology
5.5.3 Interventional Cardiology
5.5.4 Interventional Radiology
5.5.5 Y-o-Y Growth Analysis, By Application
5.5.6 Market Attractiveness Analysis, By Application
5.5.7 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Medical Procedure
6.1.3.3 By Route of Administration
6.1.3.4 By Type
6.1.3.5 By Indication
6.1.3.6 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Medical Procedure
6.1.4.3 By Route of Administration
6.1.4.4 By Type
6.1.4.5 By Indication
6.1.4.6 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Medical Procedure
6.1.5.3 By Route of Administration
6.1.5.4 By Type
6.1.5.5 By Indication
6.1.5.6 By Application
6.2 United States
6.3 Canada
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Medical Procedure Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Spago Nanomedical AB
8.3 Subhra Pharma Private Limited
8.4 Daiichi Sankyo
8.5 CMC Contrast AB
8.6 Nanopet Pharma GmbH
8.7 Guerbet Group
8.8 Bracco Imaging S.P.A
8.9 Bayer AG
8.10 Lantheus Medical Imaging (Subsidiary of Lantheus Holdings, Inc.)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
